CRISPR Therapeutics マネジメント

マネジメント基準チェック /34

CRISPR Therapeuticsの CEO はSam Kulkarniで、 Dec2017年に任命され、の在任期間は 6.92年です。の年間総報酬は$ 12.32Mで、 5.9%給与と94.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.37%を直接所有しており、その価値は$ 17.13M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と5.4年です。

主要情報

Sam Kulkarni

最高経営責任者

US$12.3m

報酬総額

CEO給与比率	5.9%
CEO在任期間	6.9yrs
CEOの所有権	0.4%
経営陣の平均在職期間	5.1yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

CEO報酬分析

CRISPR Therapeutics の収益と比較して、Sam Kulkarni の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$240m
Jun 30 2024	n/a	n/a	-US$266m
Mar 31 2024	n/a	n/a	-US$217m
Dec 31 2023	US$12m	US$725k	-US$154m
Sep 30 2023	n/a	n/a	-US$354m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$524m
Dec 31 2022	US$21m	US$700k	-US$650m
Sep 30 2022	n/a	n/a	-US$681m
Jun 30 2022	n/a	n/a	-US$633m
Mar 31 2022	n/a	n/a	US$312m
Dec 31 2021	US$17m	US$670k	US$378m
Sep 30 2021	n/a	n/a	US$412m
Jun 30 2021	n/a	n/a	US$447m
Mar 31 2021	n/a	n/a	-US$392m
Dec 31 2020	US$9m	US$625k	-US$349m
Sep 30 2020	n/a	n/a	-US$211m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$46m
Dec 31 2019	US$16m	US$550k	US$67m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$200m
Mar 31 2019	n/a	n/a	-US$185m
Dec 31 2018	US$10m	US$518k	-US$165m
Sep 30 2018	n/a	n/a	-US$117m
Jun 30 2018	n/a	n/a	-US$91m
Mar 31 2018	n/a	n/a	-US$75m
Dec 31 2017	US$7m	US$405k	-US$68m

報酬と市場: Samの総報酬 ($USD 12.32M ) は、 UK市場 ($USD 2.83M ) の同規模の企業の平均を上回っています。

報酬と収益: Samの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Sam Kulkarni (46 yo)

6.9yrs

在職期間

US$12,322,196

報酬

Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Samarth Kulkarni	CEO & Chairman	6.9yrs	US$12.32m	0.37% $ 17.1m
Raju Prasad	Chief Financial Officer	1.7yrs	US$5.91m	0.012% $ 548.8k
James Kasinger	General Counsel & Secretary	7.5yrs	US$3.51m	0.073% $ 3.4m
Shaun Foy	Founder	no data	データなし	データなし
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	データなし	データなし
Craig Mello	Scientific Founder & Advisory Board Member	no data	データなし	データなし
Chad Cowan	Scientific Founder	no data	データなし	データなし
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	データなし	データなし
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	データなし	データなし
Julianne Bruno	Chief Operating Officer	less than a year	データなし	0.016% $ 759.0k
Stephen Kennedy	Head of Technical Operations	5.1yrs	データなし	データなし
Susan Kim	Vice President of Corporate Communications & Investor Relations	no data	データなし	データなし

5.1yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: 0VRQの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Samarth Kulkarni	CEO & Chairman	6.4yrs	US$12.32m	0.37% $ 17.1m
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	データなし	データなし
Craig Mello	Scientific Founder & Advisory Board Member	no data	データなし	データなし
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	データなし	データなし
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	データなし	データなし
Douglas Treco	Lead Independent Director	4.4yrs	US$552.56k	0.0023% $ 109.6k
Ali Behbahani	Independent Director	9.6yrs	US$545.06k	0.00032% $ 15.0k
Katherine High	Independent Director	5.4yrs	US$532.56k	0% $ 0
Simeon George	Independent Director	9.6yrs	US$542.56k	0% $ 0
Stephen Elledge	Member of Scientific Advisory Board	no data	データなし	データなし
John Greene	Independent Director	5.4yrs	US$555.06k	0% $ 0
H. Fleming	Independent Director	3.4yrs	US$536.24k	0% $ 0

5.4yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: 0VRQの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

CRISPR Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

New minor risk - Share price stability

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Now 23% undervalued after recent price drop

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Now 20% undervalued

Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

Third quarter 2022 earnings released: US$2.24 loss per share (vs US$1.67 loss in 3Q 2021)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

Now 22% undervalued after recent price drop

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Investor sentiment deteriorated over the past week

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies

Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy

First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34